US Biotech Firms Ditch Wall Street — and List in Hong Kong First

Global biotech companies are increasingly choosing Hong Kong for their stock market listings over Wall Street, drawn by a growing Asian investor base and close proximity to Chinese pharmaceutical partners. The trend signals Hong Kong's rising status as an alternative capital hub for the life sciences sector.